Skip to main content
BrainCited

Ginkgo biloba 관련 노화성 인지 저하

C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.

The most studied herbal cognitive supplement. The large GEM trial (3,069 participants) found no evidence for dementia prevention in healthy elderly. However, EGb 761 standardized extract shows modest benefits in existing cognitive impairment.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dginkgo\u002Dbiloba\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

결론

The most studied herbal cognitive supplement. The large GEM trial (3,069 participants) found no evidence for dementia prevention in healthy elderly. However, EGb 761 standardized extract shows modest benefits in existing cognitive impairment.

Key Study Findings

Review
EGb761 Trials for Mild-to-Moderate Dementia-What Have We Learned in the Past 18 years?
Dose: None vs: placebo Outcome: cognitive assessment scores (MMSE, SKT, NPI) 효과: None None

대상 집단: patients with mild-to-moderate Alzheimer disease or vascular dementia

Review
Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: patients with vascular cognitive impairment and dementia

Review
Nutritional strategies against dementia in rural populations.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: Rural populations with dementia risk

Cohort Study n=64 52 weeks Open-label
Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment.
Dose: 240 mg/day vs: Standard cognitive enhancers Outcome: Cognitive responder rate and AD conversion 효과: 100% vs 59.1% responders; 0% vs 13.6% AD conversio <0.001 (responders); 0.037 (AD

대상 집단: Amyloid PET-positive MCI patients

Review
Can supplementation with antioxidants improve cognitive functions in patients with multiple sclerosis? A literature review.
Dose: None vs: None Outcome: Cognitive function in multiple sclerosis 효과: None None

대상 집단: Multiple sclerosis patients (review)

Other
Inhibition of mitochondrial oxidative stress and apoptosis in the protection of Ginkgo biloba extract 50 …
Dose: None vs: BCAS model mice without GBE50 Outcome: Cognitive impairment and white matter lesions 효과: None None

대상 집단: BCAS cerebral small vessel disease mouse model

Key Statistics

40

연구

8000

참여자

Mixed

C

등급

Referenced Papers

Pharmaceuticals (Basel, Switzerland) 2021 33 인용
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020 4 인용
Acta bio-medica : … 2018 103 인용
Age (Dordrecht, Netherlands) 2014
American family physician 2011
The Practitioner 2010
The Cochrane database … 2009 299 인용
Neuro endocrinology letters 2008
The Cochrane database … 2007 375 인용
The Proceedings of … 2002 191 인용
The Cochrane database … 2002
Current opinion in … 1998 30 인용
British journal of … 1993 8 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
120-240 mg/day standardized to 24% flavone glycosides and 6% terpene lactones

상한량: 600 mg/day (doses above show no additional benefit)

연구에서 사용된 용량

용량 기간 효과 N
None -- Mixed --
None -- Mixed --
None -- Mixed --
240 mg/day 52 weeks Positive 64
None -- Mixed --
None -- Positive --
None -- Mixed --
None -- Positive --

권장 복용 시간: With meals; may require 4-6 weeks for full effects

Safety & Side Effects

보고된 부작용

  • Headache
  • Gastrointestinal upset
  • Dizziness
  • Allergic skin reactions (rare)
  • Increased bleeding risk

알려진 상호작용

  • Anticoagulants and antiplatelet drugs (increased bleeding risk)
  • Anticonvulsants (may reduce seizure threshold)
  • SSRIs (serotonin syndrome risk, rare)
  • CYP3A4 substrates (may affect drug metabolism)

일일 최대 섭취 허용량: 600 mg/day (doses above show no additional benefit)

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Ginkgo biloba help with 노화성 인지 저하?
Based on 40 studies with 8,000 participants, there is limited but promising evidence that Ginkgo biloba may support 노화성 인지 저하 management. Our evidence grade is C (Some Evidence).
How much Ginkgo biloba should I take for 노화성 인지 저하?
Studies have used various dosages. A commonly studied range is 120-240 mg/day standardized to 24% flavone glycosides and 6% terpene lactones. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Ginkgo biloba?
Reported side effects may include Headache, Gastrointestinal upset, Dizziness, Allergic skin reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Ginkgo biloba and 노화성 인지 저하?
We rate the evidence as Grade C (Some Evidence). This rating is based on 40 peer-reviewed studies with 8,000 total participants. The overall direction of effect is mixed.

Ginkgo biloba 다른 건강 상태에 대한 근거

References

  1. [1] Bogdan-Radu Necula et al.. Am J Ther. EGb761 Trials for Mild-to-Moderate Dementia-What Have We Learned in the Past 18 years? doi:10.1097/MJT.0000000000001849 PubMed
  2. [2] Matthew J Lennon et al.. Neuropsychopharmacology. 2026. Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future. doi:10.1038/s41386-026-02331-3 PubMed
  3. [3] Xing-Yuan Li et al.. J Ethnopharmacol. 2025. Inhibition of mitochondrial oxidative stress and apoptosis in the protection of Ginkgo biloba extract 50 against cognitive impairment. doi:10.1016/j.jep.2025.120059 PubMed
  4. [4] YoungSoon Yang et al.. Front Neurol. 2025. Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment. doi:10.3389/fneur.2025.1639924 PubMed
  5. [5] Ali Rezaei et al.. Ann Med Surg (Lond). 2025. Can supplementation with antioxidants improve cognitive functions in patients with multiple sclerosis? A literature review. doi:10.1097/MS9.0000000000003124 PubMed
  6. [6] Ozra Tabatabaei-Malazy et al.. Handb Exp Pharmacol. 2025. The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection. doi:10.1007/164_2024_732 PubMed
  7. [7] Bruno S Goncalves et al.. Front Nutr. 2025. Nutritional strategies against dementia in rural populations. doi:10.3389/fnut.2025.1677197 PubMed
  8. [8] Prabhash Nath Tripathi et al.. Degener Neurol Neuromuscul Dis. 2024. Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management Using Traditional Medicinal Plants. doi:10.2147/DNND.S452009 PubMed
  9. [9] Xavier Morató et al.. J Alzheimers Dis. 2024. Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease. doi:10.3233/JAD-231372 PubMed
  10. [10] Debasis Sen et al.. Curr Alzheimer Res. 2024. Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration. doi:10.2174/0115672050309057240404075003 PubMed
  11. [11] Debashish Chowdhury et al.. Dement Geriatr Cogn Disord. 2024. Multicenter, Open-Label, Prospective Study Shows Safety and Therapeutic Benefits of a Defined Ginkgo Biloba Extract for Adults with Major Neurocognitive … doi:10.1159/000540385 PubMed
  12. [12] Wankiun Lee et al.. Medicine (Baltimore). 2024. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. doi:10.1097/MD.0000000000038067 PubMed
  13. [13] Shuge Gui et al.. Food Sci Nutr. 2024. A mixture of extracts from natural ingredients reduces the neurotoxic polarization of microglia via modulating NF-κB/NF-E2-related factor 2 activation. doi:10.1002/fsn3.4045 PubMed
  14. [14] Claire Alexander et al.. Biology (Basel). 2023. Polyherbal and Multimodal Treatments: Kaempferol- and Quercetin-Rich Herbs Alleviate Symptoms of Alzheimer's Disease. doi:10.3390/biology12111453 PubMed
  15. [15] Xavier Morató et al.. Sci Rep. 2023. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress. doi:10.1038/s41598-023-32515-6 PubMed
  16. [16] Adele E Cave et al.. Syst Rev. 2023. A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with … doi:10.1186/s13643-023-02301-6 PubMed
  17. [17] Julie Gregory et al.. Biomolecules. 2021. Neuroprotective Herbs for the Management of Alzheimer's Disease. doi:10.3390/biom11040543 PubMed
  18. [18] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
  19. [19] Carlo Tomino et al.. Pharmaceuticals (Basel). 2021. Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®). doi:10.3390/ph14040305 PubMed
  20. [20] Karin de Vries et al.. Front Nutr. 2021. The Effect of Polyphenols on Working and Episodic Memory in Non-pathological and Pathological Aging: A Systematic Review and Meta-Analysis. doi:10.3389/fnut.2021.720756 PubMed
  21. [21] Cindy Crawford et al.. J Altern Complement Med. 2021. Dietary Supplement Ingredients for Optimizing Cognitive Performance Among Healthy Adults: A Systematic Review. doi:10.1089/acm.2021.0135 PubMed
  22. [22] Ovidiu Băjenaru et al.. CNS Neurol Disord Drug Targets. 2021. Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment. doi:10.2174/1871527320666210208125524 PubMed
  23. [23] Frank Jessen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. [Pharmacological prevention of cognitive decline and dementia]. doi:10.1007/s00103-020-03120-z PubMed
  24. [24] Imane Lejri et al.. Oxid Med Cell Longev. 2019. Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence. doi:10.1155/2019/9695412 PubMed
  25. [25] Paul Fairbairn et al.. Prostaglandins Leukot Essent Fatty Acids. 2019. Combining a high DHA multi-nutrient supplement with aerobic exercise: Protocol for a randomised controlled study assessing mobility and cognitive function … doi:10.1016/j.plefa.2019.04.001 PubMed
  26. [26] Mary Butler et al.. Ann Intern Med. 2018. Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. doi:10.7326/M17-1530 PubMed
  27. [27] Ligia J Dominguez et al.. Acta Biomed. 2018. Nutritional prevention of cognitive decline and dementia. doi:10.23750/abm.v89i2.7401 PubMed
  28. [28] Arrigo F G Cicero et al.. Pharmacol Res. 2018. Botanicals and phytochemicals active on cognitive decline: The clinical evidence. doi:10.1016/j.phrs.2017.12.029 PubMed
  29. [29] Ines Banjari et al.. Front Nutr. 2018. Forestalling the Epidemics of Parkinson's Disease Through Plant-Based Remedies. doi:10.3389/fnut.2018.00095 PubMed
  30. [30] Priya Palta et al.. J Gerontol A Biol Sci Med Sci. 2017. Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study. doi:10.1093/gerona/glx076 PubMed
  31. [31] Sophie Dardenne et al.. J Alzheimers Dis. 2017. Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. doi:10.3233/JAD-170229 PubMed
  32. [32] Hong-Feng Zhang et al.. Front Aging Neurosci. 2016. An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. doi:10.3389/fnagi.2016.00276 PubMed
  33. [33] Philippa A Jackson et al.. Nutrients. 2016. DHA Supplementation Alone or in Combination with Other Nutrients Does not Modulate Cerebral Hemodynamics or Cognitive Function in Healthy Older … doi:10.3390/nu8020086 PubMed
  34. [34] Monisha Sharma et al.. J Am Geriatr Soc. 2016. Inflammatory Biomarkers and Cognitive Decline: The Ginkgo Evaluation of Memory Study. doi:10.1111/jgs.14140 PubMed
  35. [35] Andreas Ströhle et al.. Am J Geriatr Psychiatry. 2015. Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition … doi:10.1016/j.jagp.2015.07.007 PubMed
  36. [36] P Lehert et al.. Climacteric. 2015. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis. doi:10.3109/13697137.2015.1078106 PubMed
  37. [37] Andreas G Franke et al.. Age (Dordr). 2014. The use of Ginkgo biloba in healthy elderly. doi:10.1007/s11357-013-9550-y PubMed
  38. [38] Christian Ude et al.. Clin Pharmacokinet. 2013. Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. doi:10.1007/s40262-013-0074-5 PubMed
  39. [39] Jerome Sarris et al.. CNS Drugs. 2013. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. doi:10.1007/s40263-013-0059-9 PubMed
  40. [40] Hélène Amieva et al.. PLoS One. 2013. Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study. doi:10.1371/journal.pone.0052755 PubMed
  41. [41] Nicola T Lautenschlager et al.. Int Psychogeriatr. 2012. Ginkgo biloba extract EGb 761® in the context of current developments in the diagnosis and treatment of age-related cognitive decline … doi:10.1017/S1041610212001019 PubMed
  42. [42] Bradford T Winslow et al.. Am Fam Physician. 2011. Treatment of Alzheimer disease. PubMed
  43. [43] Louise A Brown et al.. Exp Aging Res. 2010. Supplementing cognitive aging: a selective review of the effects of ginkgo biloba and a number of everyday nutritional substances. doi:10.1080/03610730903417960 PubMed
  44. [44] Lei Feng. JAMA. 2010. Ginkgo biloba and cognitive decline. doi:10.1001/jama.2010.434 PubMed
  45. [45] Klaus P Ebmeier. Practitioner. 2010. Normal cognitive decline or dementia? PubMed
  46. [46] Beth E Snitz et al.. JAMA. 2009. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. doi:10.1001/jama.2009.1913 PubMed
  47. [47] Jacqueline Birks et al.. Cochrane Database Syst Rev. 2009. Ginkgo biloba for cognitive impairment and dementia. doi:10.1002/14651858.CD003120.pub3 PubMed
  48. [48] Nicola Coley et al.. Epidemiol Rev. 2008. Dementia prevention: methodological explanations for inconsistent results. doi:10.1093/epirev/mxn010 PubMed
  49. [49] H H Dodge et al.. Neurology. 2008. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. doi:10.1212/01.wnl.0000303814.13509.db PubMed
  50. [50] Joseph A Araujo et al.. Can Vet J. 2008. Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine. PubMed
  51. [51] Marek Jarema. Neuro Endocrinol Lett. 2008. Herbal drug treatment. PubMed
  52. [52] J Birks et al.. Cochrane Database Syst Rev. 2007. Ginkgo biloba for cognitive impairment and dementia. doi:10.1002/14651858.CD003120.pub2 PubMed
  53. [53] Michael Grundman et al.. Proc Nutr Soc. 2002. Antioxidant strategies for Alzheimer's disease. doi:10.1079/PNS2002146 PubMed
  54. [54] J Birks et al.. Cochrane Database Syst Rev. 2002. Ginkgo biloba for cognitive impairment and dementia. doi:10.1002/14651858.CD003120 PubMed
  55. [55] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
  56. [56] W J Riedel et al.. Curr Opin Clin Nutr Metab Care. 1998. Nutrients, age and cognitive function. doi:10.1097/00075197-199811000-00017 PubMed
  57. [57] D M Warburton. Br J Clin Pharmacol. 1993. Ginkgo biloba extract and cognitive decline. doi:10.1111/j.1365-2125.1993.tb04213.x PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.